Amgen Inc. AMGN | NASDAQ
Next Earnings: Jul 31, 2026
Company Overview:
10 Year AMGN Performance Metrics:
AMGN Dividend Payments, Yield & Share Price charts
Unlock All Reports & Research Dividend Stocks.
[lev_ptables no_sale]AMGN Dividend Safety: Payout & Dividend to Free Cash Flow Ratios.
AMGN Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
AMGN Dividends Info:
AMGN Dividend History: Dates, Payments & Yield list
Below is a schedule of all AMGN dividend payments, ex-dates, share price on the day of the payment as well as TTM & forward yield
| Ex-Date | Payment Date | Amount | TTM Yield | Forward Yield | Price on Ex-Date |
|---|---|---|---|---|---|
| 05/15/2026 | 06/05/2026 | $2.520 | 3% | 2.88% | $349.58 |
| 02/13/2026 | 03/06/2026 | $2.520 | 2.62% | 2.73% | $369.53 |
| 11/21/2025 | 12/12/2025 | $2.380 | 2.82% | 3% | $317.74 |
| 08/22/2025 | 09/12/2025 | $2.380 | 3.2% | 3.44% | $276.39 |
| 05/16/2025 | 06/06/2025 | $2.380 | 3.4% | 3.28% | $290.33 |
| 02/14/2025 | 03/07/2025 | $2.380 | 3.14% | 2.93% | $324.86 |
| 11/18/2024 | 12/09/2024 | $2.250 | 3.23% | 3.24% | $277.63 |
| 08/16/2024 | 09/06/2024 | $2.250 | 2.76% | 2.81% | $320.56 |
| 05/17/2024 | 06/07/2024 | $2.250 | 0% | 2.95% | $305.02 |
| 05/16/2024 | 06/07/2024 | $2.250 | 2.78% | 2.95% | $305.02 |
| 02/15/2024 | 03/07/2024 | $2.250 | 2.99% | 3.3% | $272.86 |
| 11/16/2023 | 12/08/2023 | $2.130 | 3.17% | 3.17% | $269.12 |
| 08/17/2023 | 09/08/2023 | $2.130 | 3.16% | 3.28% | $259.43 |
| 05/17/2023 | 06/08/2023 | $2.130 | 3.62% | 3.86% | $220.76 |
| 02/14/2023 | 03/08/2023 | $2.130 | 2.49% | 3.73% | $228.43 |
| 11/16/2022 | 12/08/2022 | $1.940 | 2.73% | 2.72% | $285.57 |
| 08/17/2022 | 09/08/2022 | $1.940 | 3.03% | 3.16% | $245.45 |
| 05/16/2022 | 06/08/2022 | $1.940 | 3.03% | 3.16% | $245.48 |
| 02/14/2022 | 03/08/2022 | $1.940 | 3.22% | 3.36% | $231.10 |
| 11/15/2021 | 12/08/2021 | $1.760 | 3.39% | 3.3% | $213.53 |
| 08/16/2021 | 09/08/2021 | $1.760 | 2.98% | 3.19% | $220.87 |
| 05/14/2021 | 06/08/2021 | $1.760 | 2.67% | 2.97% | $236.82 |
| 02/11/2021 | 03/08/2021 | $1.760 | 2.79% | 3.09% | $227.81 |
| 11/13/2020 | 12/08/2020 | $1.600 | 2.7% | 2.8% | $228.94 |
| 08/14/2020 | 09/08/2020 | $1.600 | 2.61% | 2.65% | $241.18 |
| 05/15/2020 | 06/08/2020 | $1.600 | 2.54% | 2.83% | $225.75 |
| 02/13/2020 | 03/06/2020 | $1.600 | 2.67% | 3.04% | $210.65 |
| 11/14/2019 | 12/06/2019 | $1.450 | 2.65% | 2.48% | $233.77 |
| 08/14/2019 | 09/06/2019 | $1.450 | 2.85% | 2.79% | $207.73 |
| 05/16/2019 | 06/07/2019 | $1.450 | 3.26% | 3.3% | $175.51 |
| 02/14/2019 | 03/08/2019 | $1.450 | 2.9% | 3.21% | $180.87 |
| 11/15/2018 | 12/07/2018 | $1.320 | 2.74% | 2.76% | $191.44 |
| 08/16/2018 | 09/07/2018 | $1.320 | 2.6% | 2.69% | $196.30 |
| 05/16/2018 | 06/08/2018 | $1.320 | 2.84% | 2.86% | $184.30 |
| 02/14/2018 | 03/08/2018 | $1.320 | 2.66% | 2.82% | $187.16 |
| 11/16/2017 | 12/08/2017 | $1.150 | 2.69% | 2.62% | $175.41 |
| 08/15/2017 | 09/08/2017 | $1.150 | 2.62% | 2.55% | $180.64 |
| 05/15/2017 | 06/08/2017 | $1.150 | 2.69% | 2.83% | $162.65 |
| 02/13/2017 | 03/08/2017 | $1.150 | 2.48% | 2.59% | $177.78 |
| 11/14/2016 | 12/08/2016 | $1.000 | 2.73% | 2.85% | $140.59 |
| 08/15/2016 | 09/08/2016 | $1.000 | 2.17% | 2.34% | $170.97 |
| 05/13/2016 | 06/08/2016 | $1.000 | 2.35% | 2.53% | $158.00 |
| 02/11/2016 | 03/08/2016 | $1.000 | 2.38% | 2.77% | $144.63 |
| 11/12/2015 | 12/07/2015 | $0.790 | 2.09% | 2% | $158.30 |
| 08/13/2015 | 09/08/2015 | $0.790 | 1.77% | 2.04% | $154.56 |
| 05/12/2015 | 06/05/2015 | $0.790 | 1.77% | 2.01% | $157.25 |
| 02/10/2015 | 03/06/2015 | $0.790 | 1.72% | 2.04% | $154.88 |
| 11/10/2014 | 12/05/2014 | $0.610 | 1.5% | 1.44% | $169.24 |
| 08/12/2014 | 09/05/2014 | $0.610 | 1.82% | 1.77% | $137.88 |
| 05/13/2014 | 06/06/2014 | $0.610 | 1.95% | 2.07% | $117.82 |
| 02/11/2014 | 03/07/2014 | $0.610 | 1.67% | 2% | $122.26 |
| 11/12/2013 | 12/06/2013 | $0.470 | 1.67% | 1.65% | $114.12 |
| 08/14/2013 | 09/06/2013 | $0.470 | 1.66% | 1.69% | $111.01 |
| 05/14/2013 | 06/07/2013 | $0.470 | 1.54% | 1.9% | $98.81 |
| 02/11/2013 | 03/07/2013 | $0.470 | 1.83% | 2.02% | $92.95 |
| 11/13/2012 | 12/07/2012 | $0.360 | 1.68% | 1.63% | $88.32 |
| 08/14/2012 | 09/07/2012 | $0.360 | 1.63% | 1.72% | $83.96 |
| 05/14/2012 | 06/07/2012 | $0.360 | 1.82% | 2.08% | $69.10 |
| 02/13/2012 | 03/07/2012 | $0.360 | 1.35% | 2.15% | $66.95 |
| 11/15/2011 | 12/08/2011 | $0.280 | 0.99% | 1.92% | $58.40 |
| 08/16/2011 | 09/08/2011 | $0.280 | 0.55% | 2.02% | $55.31 |
Projected Future Returns & Dividends for AMGN
Based on past 10-year performance, here are AMGN growth metrics:
Share price CAGR of +8.28%
Dividend CAGR of +9.69%
Using AMGN CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| AMGN (DRIP) | AMGN - No DRIP | |
|---|---|---|
| Current Price | $385.69 | $385.69 |
| Start Shares | 25.93 | 25.93 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 34.18 | 25.93 |
| Dividends Payment | $6.36 | $6.36 |
| Annual Dividends | $869 | $659 |
| Yield on cost | 8.69% | 6.59% |
| Share Price | $854.14 | $854.14 |
| Total Dividends | $4,795 | $4,104 |
| Final Value | $29,195 | $26,250 |
NOTE: Above numbers are our estimate based on AMGN's Dividend and Price CAGR over past 10 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
[lev_ptables no_sale]Company Info
Amgen Inc. (AMGN) had its IPO on 1983-06-17, and is trader on NASDAQ stock exchange.
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
AMGN website: https://www.amgen.com
